血液生物標誌物預測缺氧缺血性腦病中的腦性麻痺及認知遲緩：HEAL隨機對照試驗的次級分析

// Blood-Based Biomarkers Predict Cerebral Palsy and Cognitive Delay in Hypoxic-Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized Controlled Trial

本研究分析新生兒早期血液生物標誌物，以預測中重度缺氧缺血性腦病變（HIE）嬰兒的腦性麻痺（CP）及認知/語言發展遲緩｜180名嬰兒數據顯示，第2天的Tau蛋白標誌物對CP預測表現優異，與MRI結果相當｜Tau也是認知與語言遲緩的最佳整體預測指標，為HIE後預後提供重要參考。

// This study analyzed blood biomarkers in the first days of life to predict cerebral palsy (CP) and cognitive/language delay in infants with moderate-severe hypoxic-ischemic encephalopathy (HIE). Using data from 180 infants in the HEAL Trial, the biomarker Tau on day 2 showed excellent prediction of CP, matching detailed MRI results. Different biomarkers predicted cognitive/language delay, but Tau remained the best overall predictor. Tau's early measurement provides valuable prognostic information for outcomes after HIE.

Published 2026年7月1日